Details for Patent: 10,881,663

Which drugs does patent 10,881,663 protect, and when does it expire?

Patent 10,881,663 protects ANJESO and is included in one NDA.

This patent has thirteen patent family members in seven countries.

Summary for Patent: 10,881,663

Patent landscape, scope, and claims:

Title:	Method of treating pain in elderly patients with mild renal impairment
Abstract:	The present disclosure relates to administration of meloxicam intravenously, for treatment of pain, in patients who are at least 65 years old and have mild renal impairment, which can provide fast onset of pain relief suitable for management of acute pain as well as moderate to severe pain.
Inventor(s):	Mack; Randall J. (Malvern, PA), McCallum; Stewart (Malvern, PA), Gomez; Alexis (Malvern, PA), Freyer; Alex (Malvern, PA)
Assignee:	BAUDAX BIO, INC. (Malvern, PA)
Application Number:	16/297,020
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 10,881,663

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Baudax	ANJESO	meloxicam	SOLUTION;INTRAVENOUS	210583-001	Feb 20, 2020		DISCN	Yes	No	10,881,663					MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INTRAVENOUS INJECTION IN PATIENTS WITH MILD RENAL IMPAIRMENT

International Family Members for US Patent 10,881,663

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2019231858
Australia	2019364416
Canada	3117209
China	111201020
China	111356453
European Patent Office	3761977